BackCleveland BioLabs Overview

Cleveland BioLabs Total Current Liabilities

Cleveland BioLabs's total current liabilities is $300K.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$300623.00
61.82% YoYΔ $-486712.00 vs prior year quarter

Peer trimmed avg / median

Loading

Cleveland BioLabs Total Current Liabilities History

Loading

Cleveland BioLabs vs. peers: Total Current Liabilities Comparison

Loading

Cleveland BioLabs Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cleveland BioLabs (CBLI) FAQ

As of the most recent data (June 2021), CBLI shows a total current liabilities of $300K. That compares with $790K in the prior-year period — down 61.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CBLI's total current liabilities is now $300K (was $790K) — a 61.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cleveland BioLabs is outperforming or lagging.

Tracking CBLI's total current liabilities over time shows whether Cleveland BioLabs is scaling, shrinking, or reshaping that part of the business. The current reading is $300K That compares with $790K in the prior-year period — down 61.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Cleveland BioLabs's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $300K) with ownership activity and broader fundamentals.

Cleveland BioLabs's total current liabilities is $300K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.